BeiGene
BGNE
HK$1,433
Share price
0.49%
Change (1 day)
32.28%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - Total debt
Total debt on the balance sheet as of September 2024 : HK$8.54 Billion
According to BeiGene 's latest financial reports the company's total debt is HK$8.54 Billion. A company’s total debt is the sum of all current and non-current debts.
BeiGene - Total debt on balance sheet (from 2014 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | HK$7.26 B | 55.83% |
| 2022-12-31 | HK$4.66 B | -13.93% |
| 2021-12-31 | HK$5.41 B | 24.33% |
| 2020-12-31 | HK$4.35 B | 101.69% |
| 2019-12-31 | HK$2.15 B | 39.03% |
| 2018-12-31 | HK$1.55 B | 20.73% |
| 2017-12-31 | HK$1.28 B | 860.17% |
| 2016-12-31 | HK$0.13 B | -16.81% |
| 2015-12-31 | HK$0.16 B | 50.1% |
| 2014-12-31 | HK$0.10 B | -49.42% |
| 2013-12-31 | HK$0.21 B |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 | N/A | N/A | 🇺🇸 USA |
 | HK$3.91 B | -54.20% | 🇺🇸 USA |